- Home
- LLY
as 03-25-2025 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 830.4B | IPO Year: | N/A |
| Target Price: | $1000.53 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 11.71 | EPS Growth: | 101.90 |
| 52 Week Low/High: | $711.40 - $972.53 | Next Earning Date: | 05-01-2025 |
| Revenue: | $45,042,700,000 | Revenue Growth: | 32.00% |
| Revenue Growth (this year): | 32.92% | Revenue Growth (next year): | 18.30% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Mar 3 '25 | Sell | $928.71 | 220,000 | $204,326,150.89 | 96,032,486 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 25 '25 | Sell | $905.96 | 225,000 | $203,190,794.31 | 96,032,486 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 24 '25 | Sell | $59,386.22 | 60,432 | $1,648,756,039.51 | 96,032,486 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 21 '25 | Sell | $885.59 | 99,452 | $87,786,505.01 | 96,032,486 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 20 '25 | Sell | $878.84 | 14,685 | $12,893,352.83 | 96,032,486 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 19 '25 | Sell | $878.96 | 9,985 | $8,771,285.36 | 96,032,486 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 13 '25 | Sell | $880.55 | 35,446 | $31,175,396.35 | 96,032,486 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Feb 6 '25 | Sell | $876.89 | 210,000 | $183,567,261.66 | 96,032,486 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Insider Monkey
7 hours ago
Is Eli Lilly and Company (NYSE:LLY) The Best Stocks to Buy Now For the Long Term?
Pharmaceutical Technology
8 hours ago
Trump tariffs drive pharma manufacturing to US but risk inflation and disruption
Yahoo Finance
16 hours ago
GLP-1s boost pharma R&D projected return on investment: Deloitte
Investor's Business Daily
a day ago
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.
Fox Business
a day ago
Hyundai to invest $20B in US manufacturing
Motley Fool
a day ago
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
Insider Monkey
a day ago
Was Jim Cramer Right About Eli Lilly and Company (LLY)?
MT Newswires
a day ago
Eli Lilly Could See Higher Q1 Sales for Zepbound, UBS Says
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.